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Cyclin D1 was originally identified as a candidate 
oncogene activated in a subset of parthyroid tumors 
through genetic rearrangement [1]. We now understand 
that Cyclin D1 is a member of a family of cyclins that 
regulate progression through the cell cycle in a stepwise 
fashion from commitment to DNA replication through 
to cell division and cytokinesis [2]. Cyclin D1 binds the 
cyclin dependent kinases cdk4 and 6 to phosphorylate the 
retinoblastoma protein (RB) and initiate transition from 
G1 to S-phase. In addition to interacting with its principal 
substrate, RB, cyclin D1-Cdk4 acts on other substrates 
that  have  well  defined  roles  within,  carcinogenesis 
(Smad3) and mitochondrial function (Nrf1) [3]. There 
are a number of cyclin D1 functions that are independent 
of an associated kinase. Cyclin D1 is a modulator of 
co-regulators such as BRCA1 and nuclear receptors. 
Hulit et al was the first to show the abundance of cyclin 
D1 determines TF recruitment in the context of local 
chromatin, and did so in vivo [4]. Fu et al was the first 
to show cyclin D1 is recruited in the context of local 
chromatin, which in turn recruited chromatin modifying 
proteins (SUV39, HP1α, p300, HDAC1, and HDAC 3) 
and altered the acetylation and methylation of chromatin 
associated histones [5]. Cyclin D1 thus regulates 
transcription at the chromatin level by interacting with 
histone deacetylases and various transcription factors 
to regulate genes that contribute to differentiation 
and proliferation [4]. Cyclin D1 promoter occupancy 
assessed by ChIP-ChIP technology mapped cyclin D1 to 
approximately 900 genes [6]. We extended these studies 
to the whole genome to map at high resolution, using 
ChIP-Seq, the global genomic footprint for cyclin D1 [7]. 
We identified 3,222 regions (intervals) associated with 
cyclin D1, approximately 70% of these intervals were 
within 10kb of 2, 840 genes with a high density located 
within 500bp of the transcriptional start point. We next 
investigated the transcription factor motifs enriched at the 
interval region and found the top hits included ERα, Sp1 
and Ctcf. Interestingly Ctcf is a zinc finger DNA binding 
protein that regulates transcription, governs enhancer 
function and is involved in sister chromatid cohesion. 
We next interrogated the functional pathways 
associated with the genes bound by cyclin D1. One of 
the most enriched terms was cell division; most of the 
genes being involved in G2/M phase and cellular mitosis. 
Increased abundance of cyclin D1 during G2/M has 
previously been described [8]. We used ChIP to verify 
that cyclin D1 bound the regulatory regions of genes 
involved in mitosis and QT-PCR to demonstrate that 
the gene transcripts were induced in cyclin D1 rescued 
Ccnd1-/- fibroblasts. Misregulation of genes that govern the 
mitotic phase often lead to chromosomal instability (CIN). 
Whether a cause or a consequence of tumorigenesis, 
CIN itself is recognized as promoting transformation, 
associated with poor prognosis and metastasis. 
Understanding the transcriptional role of cyclin D1 in 
promoting CIN is of considerable clinical importance 
since it is commonly over expressed in breast, pancreatic, 
lung cancer and lymphoma.
In  Ccnd1-/-  fibroblasts  rescued  with  cyclin  D1, 
the induction of polyploidy occurred in 3 cell division 
assessed by FACS analysis. In order to further classify 
the chromosomal abnormalities we employed spectral 
karyotyping (SKY), a whole genome painting assay that 
can recognize complex genomic rearrangements. Cyclin 
D1 induced aneuploidy in a relatively short amount of 
time and a large number of translocations, both reciprocal 
and nonreciprocal. Nonreciprocal translocations can be 
potently transforming since they can carry oncogenes at 
the breakpoint. A leading cause of aneuploidy is multipolar 
spindles caused by abnormal number or structure of 
centrosomes.  In  order  to  investigate  the  fidelity  of 
the mitotic process we used high-resolution confocal 
microscopy to observe fibroblasts stained with markers 
of spindles (α-tubulin) and centrosomes (γ-tubulin). In 
cyclin D1 rescued Ccnd1-/- fibroblasts over 50% of the 
cells exhibited multiple centrosomes that give rise to 
increase multipolar spindles in prometaphase/metaphase. 
The abnormalities were also evident at the mitotic plate 
since measurements of the plate width were significantly 
increased in cyclin D1 rescued fibroblasts.
We developed mouse model systems to investigate 
the potential for cyclin D1 to induce CIN in vivo. In a 
mammary gland specific Tet-inducible model the acute 
expression profile regulated by cyclin D1 after 7 days 
was enriched in genes that rank highly with CIN. We 
also used a mammary gland targeted model (MMTV) 
to continuously express cyclin D1. The mice started 
to develop mammary gland tumors at 400 days and the 
tumor-free incidence was 40% in MMTV-cyclin D1. The 
gene expression profile of the tumors showed enrichment 
for the CIN signature. We next compared cyclin D1 
expression and the highest ranking CIN genes to a breast 
cancer expression database and discovered that expression 
of genes promoting CIN are highly enriched in luminal 
subtype and that high cyclin D1 and CIN expression Oncotarget 2012; 3:  224-225 225 www.impactjournals.com/oncotarget
correlate specifically in the luminal B subtype. There is 
increasing interest in employing drugs in the clinic that 
exploit CIN in tumors. The high CIN expression index in 
luminal B breast cancer provides a basis for using Cdk and 
CIN inhibitors as a targeted therapeutic approach.
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